# Jyong Biotech Ltd. (Nasdaq: MENS) announced updated statistical analyses for key blood biochemical markers from its Phase II clinical trial of MCS-8 (PCP) conducted in Taiwan.

*biotech · news · 2026-01-30 · The Manila Times*

## Key points

- Jyong Biotech's MCS-8 showed statistically significant cholesterol reduction in a Phase II clinical trial.
- No increase in serum LDH was observed in the MCS-8 group, suggesting lower risk of cellular damage.
- Jyong Biotech is considering expanding MCS-8's indications to lipid management and cardiovascular diseases.
- MCS-8's technology enhances bioavailability, potentially enabling multiple dosage forms and indications.

**Companies:** Jyong Biotech Ltd.
**Countries:** Taiwan, United States, European Union

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/01/30/tmt-newswire/globenewswire/jyong-biotech-subsidiary-announces-phase-ii-clinical-data-on-cholesterol-and-ldh-indicators-for-mcs-8-pcp-indicating-potential-in-prostate-cancer-prevention-and-metabolic-value/2268715)

---

Canonical: https://newsio.io/n/c4374ce8-1ade-4d26-a523-1b7d1c8511ec/jyong-biotech-ltd-nasdaq-mens-announced-updated-statistical-analyses-for-key-blo
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works